Through the clarification of underlying mechanisms and the proposal of effective interventions, this review strives to contribute to the advancement of personalized strategies that optimize the therapeutic benefits of PD-1 inhibitors in NSCLC patients, irrespective of their sarcopenia status. Here, PDCD1 is linked to non-small cell lung carcinoma.